Stocks to buy in 2026 for long term: Dr Lal PathLabs, IDFC First Bank among 5 stocks that could give 10-30% return

Leading brokerages have issued buy recommendations on five stocks across healthcare, banking, defence, pharma and specialty chemicals for long-term investors in 2026. Nuvama raised its target on Dr Lal PathLabs to Rs 2,140 (21 percent upside) and upgraded IDFC First Bank to buy with a Rs 95 target (18 percent upside). Anand Rathi retained buy on Jubilant Ingrevia (target Rs 980, 35 percent upside) and Hindustan Aeronautics (target Rs 5,431, 18 percent upside), while Emkay Global kept a buy on Granules India with a Rs 950 target (14 percent upside).